Hyperoside pre-treatment prevents glomerular basement membrane damage in diabetic nephropathy by inhibiting podocyte heparanase expression

Abstract Glomerular basement membrane (GBM) damage plays a pivotal role in pathogenesis of albuminuria in diabetic nephropathy (DN). Heparan sulfate (HS) degradation induced by podocyte heparanase is the major cause of GBM thickening and abnormal perm-selectivity. In the present study, we aimed to e...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xiaofei An, Lin Zhang, Yanggang Yuan, Bin Wang, Qiuming Yao, Ling Li, Jisheng Zhang, Ming He, Jinan Zhang
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/cb6d760cbd35466ebef99136a088e90b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cb6d760cbd35466ebef99136a088e90b
record_format	dspace
spelling	oai:doaj.org-article:cb6d760cbd35466ebef99136a088e90b2021-12-02T16:06:43ZHyperoside pre-treatment prevents glomerular basement membrane damage in diabetic nephropathy by inhibiting podocyte heparanase expression10.1038/s41598-017-06844-22045-2322https://doaj.org/article/cb6d760cbd35466ebef99136a088e90b2017-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-06844-2https://doaj.org/toc/2045-2322Abstract Glomerular basement membrane (GBM) damage plays a pivotal role in pathogenesis of albuminuria in diabetic nephropathy (DN). Heparan sulfate (HS) degradation induced by podocyte heparanase is the major cause of GBM thickening and abnormal perm-selectivity. In the present study, we aimed to examine the prophylactic effect of hyperoside on proteinuria development and GBM damage in DN mouse model and the cultured mouse podocytes. Pre-treatment with hyperoside (30 mg/kg/d) for four weeks could significantly decrease albuminuria, prevent GBM damage and oxidative stress in diabetes mellitus (DM) mice. Immunofluorescence staining, Real time PCR and Western blot analysis showed that decreased HS contents and increased heparanase expression in DN mice were also significantly improved by hyperoside pre-treatment. Meanwhile, transmission electron microscope imaging showed that hyperoside significantly alleviated GBM thickening in DN mice. In addition, hyperoside pre-treatment inhibited the increased heparanase gene (HPR1) promoter activity and heparanase expression induced by high glucose or reactive oxidative species (ROS) in cultured podocytes. Our data suggested that hyperoside has a prophylactic effect on proteinuria development and GBM damage in DM mice by decreasing podocyte heparanase expression.Xiaofei AnLin ZhangYanggang YuanBin WangQiuming YaoLing LiJisheng ZhangMing HeJinan ZhangNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-12 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Xiaofei An Lin Zhang Yanggang Yuan Bin Wang Qiuming Yao Ling Li Jisheng Zhang Ming He Jinan Zhang Hyperoside pre-treatment prevents glomerular basement membrane damage in diabetic nephropathy by inhibiting podocyte heparanase expression
description	Abstract Glomerular basement membrane (GBM) damage plays a pivotal role in pathogenesis of albuminuria in diabetic nephropathy (DN). Heparan sulfate (HS) degradation induced by podocyte heparanase is the major cause of GBM thickening and abnormal perm-selectivity. In the present study, we aimed to examine the prophylactic effect of hyperoside on proteinuria development and GBM damage in DN mouse model and the cultured mouse podocytes. Pre-treatment with hyperoside (30 mg/kg/d) for four weeks could significantly decrease albuminuria, prevent GBM damage and oxidative stress in diabetes mellitus (DM) mice. Immunofluorescence staining, Real time PCR and Western blot analysis showed that decreased HS contents and increased heparanase expression in DN mice were also significantly improved by hyperoside pre-treatment. Meanwhile, transmission electron microscope imaging showed that hyperoside significantly alleviated GBM thickening in DN mice. In addition, hyperoside pre-treatment inhibited the increased heparanase gene (HPR1) promoter activity and heparanase expression induced by high glucose or reactive oxidative species (ROS) in cultured podocytes. Our data suggested that hyperoside has a prophylactic effect on proteinuria development and GBM damage in DM mice by decreasing podocyte heparanase expression.
format	article
author	Xiaofei An Lin Zhang Yanggang Yuan Bin Wang Qiuming Yao Ling Li Jisheng Zhang Ming He Jinan Zhang
author_facet	Xiaofei An Lin Zhang Yanggang Yuan Bin Wang Qiuming Yao Ling Li Jisheng Zhang Ming He Jinan Zhang
author_sort	Xiaofei An
title	Hyperoside pre-treatment prevents glomerular basement membrane damage in diabetic nephropathy by inhibiting podocyte heparanase expression
title_short	Hyperoside pre-treatment prevents glomerular basement membrane damage in diabetic nephropathy by inhibiting podocyte heparanase expression
title_full	Hyperoside pre-treatment prevents glomerular basement membrane damage in diabetic nephropathy by inhibiting podocyte heparanase expression
title_fullStr	Hyperoside pre-treatment prevents glomerular basement membrane damage in diabetic nephropathy by inhibiting podocyte heparanase expression
title_full_unstemmed	Hyperoside pre-treatment prevents glomerular basement membrane damage in diabetic nephropathy by inhibiting podocyte heparanase expression
title_sort	hyperoside pre-treatment prevents glomerular basement membrane damage in diabetic nephropathy by inhibiting podocyte heparanase expression
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/cb6d760cbd35466ebef99136a088e90b
work_keys_str_mv	AT xiaofeian hyperosidepretreatmentpreventsglomerularbasementmembranedamageindiabeticnephropathybyinhibitingpodocyteheparanaseexpression AT linzhang hyperosidepretreatmentpreventsglomerularbasementmembranedamageindiabeticnephropathybyinhibitingpodocyteheparanaseexpression AT yanggangyuan hyperosidepretreatmentpreventsglomerularbasementmembranedamageindiabeticnephropathybyinhibitingpodocyteheparanaseexpression AT binwang hyperosidepretreatmentpreventsglomerularbasementmembranedamageindiabeticnephropathybyinhibitingpodocyteheparanaseexpression AT qiumingyao hyperosidepretreatmentpreventsglomerularbasementmembranedamageindiabeticnephropathybyinhibitingpodocyteheparanaseexpression AT lingli hyperosidepretreatmentpreventsglomerularbasementmembranedamageindiabeticnephropathybyinhibitingpodocyteheparanaseexpression AT jishengzhang hyperosidepretreatmentpreventsglomerularbasementmembranedamageindiabeticnephropathybyinhibitingpodocyteheparanaseexpression AT minghe hyperosidepretreatmentpreventsglomerularbasementmembranedamageindiabeticnephropathybyinhibitingpodocyteheparanaseexpression AT jinanzhang hyperosidepretreatmentpreventsglomerularbasementmembranedamageindiabeticnephropathybyinhibitingpodocyteheparanaseexpression
_version_	1718384931564945408

Hyperoside pre-treatment prevents glomerular basement membrane damage in diabetic nephropathy by inhibiting podocyte heparanase expression

Ejemplares similares